<?xml version='1.0' encoding='UTF-8'?><?xml-stylesheet href='static/style.xsl' type='text/xsl'?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-22T09:53:52Z</responseDate><request verb="GetRecord" identifier="oai:ecommons.cornell.edu:1813/37070" metadataPrefix="dim">https://ecommons.cornell.edu/server/oai/request</request><GetRecord><record><header><identifier>oai:ecommons.cornell.edu:1813/37070</identifier><datestamp>2026-05-14T13:53:53Z</datestamp><setSpec>com_1813_35</setSpec><setSpec>col_1813_47</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="author" lang="en_US">Rosenthal, Joseph</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="chair" lang="en_US">Putnam, David A.</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="committeeMember" lang="en_US">Chang, Yung-Fu</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="committeeMember" lang="en_US">Shuler, Michael Louis</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="committeeMember" lang="en_US">Delisa, Matthew</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2014-07-28T19:24:52Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2019-05-26T06:01:58Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued" lang="en_US">2014-05-25</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://hdl.handle.net/1813/37070</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="bibid">8641156</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">The greatest strides in vaccine delivery over the last decade have come primarily from a new class of nanoparticulate antigen carrier that focuses on reverse-engineering the pathogen-immune cell interaction on the molecular level. Such "pathogen-like particles", or PLPs, take an elegant approach to biomimicry, attempting to artificially isolate or recreate a pathogen's natural ability to stimulate a targeted immune response. In this work, we focused on the transformation of the probiotic E. coli strain Nissle 1917 into an outer membrane vesicle (OMV) platform for TH1-biasing delivery of a variety of recombinant antigens. We hypothesize that by harnessing the natural immunomodulation of the Nissle 1917 (EcN) bacterium, and pairing this immunomodulation with appropriate vaccine targets that require potent TH1-biasing vaccine responses, we can engineer a recombinant antigen delivery platform that uniquely enhances antigen-specific immunity through pathogen-mimetic vaccination. As bionanoparticulate PLPs often suffer from requiring multiple boosts and external adjuvants to achieve pathogen-mimetic memory responses, we further enhanced our EcN OMV platform with controlled release delivery using injectable polymeric microspheres as a transient OMV depot. From the immunological characterization of free and encapsulated EcN OMVs' vaccine capability, two vaccine targets were chosen to demonstrate the efficacy of the OMVs as a PLP platform for vaccine delivery. To test the capacity of the OMVs to functionally display and vaccinate against a heterologous antigen of viral origin, OMVs expressing a subunit of H1N1 hemagglutinin were produced and tested on BALB/c mice. Not only did the resulting immunological assays for vaccine response show great promise for a protective response, generating a 2.6-fold increase in IgG2a:IgG1 titers and a 8.1iii  fold increase in IFN-[gamma]:IL-4 T-cell secretion versus a gold-standard control, but further analysis using hemagglutination-inhibition assays demonstrated >50-fold enhancement in cross-strain protection against H3N2. Secondly, to test EcN OMVs' capacity to direct unique immunomodulation to less standard vaccine targets, OMVs expressing the peanut allergen Arah2 were produced as both a prophylactic vaccine (for preventing peanut allergy) and an immunotherapy (for treating extent peanut allergy). Using a BALB/c mouse model for peanut allergy sensitization, a free EcN OMV vaccine dose was administered prior to sensitization, which following anaphylactic challenge post-sensitization resulted in protective survival of 100% of vaccinated mice. Encapsulated controlled release of lower doses of the Arah2-displaying EcN OMVs administered following sensitization were also successful at protecting >50% of mice from some level of anaphylaxis post-challenge while minimizing side-effects relative to traditional sublingual immunotherapy. The engineering and in vitro/in vivo testing of EcN OMVs as vaccine antigen carriers demonstrated promising efficacy as a pathogen-mimetic platform for protective immunomodulation. Successful testing with a variety of recombinant antigens provides the foundation upon which further development of the EcN OMV platform can lead to a promising host of PLP vaccines. iv</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso" lang="en_US">en_US</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Outer membrane vesicle</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Vaccine delivery</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Pathogen-like particle</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">Engineered Outer Membrane Vesicles Derived From Probiotic Escherichia Coli Nissle 1917 As Recobinant Subunit Antigen Carreirs For The Development Of Pathogen-Mimetic Vaccines</dim:field>
   <dim:field mdschema="dc" element="type" lang="en_US">dissertation or thesis</dim:field>
   <dim:field mdschema="dc" element="format" qualifier="mimetype">application/pdf</dim:field>
   <dim:field mdschema="thesis" element="degree" qualifier="discipline">Biomedical Engineering</dim:field>
   <dim:field mdschema="thesis" element="degree" qualifier="grantor" lang="en_US">Cornell University</dim:field>
   <dim:field mdschema="thesis" element="degree" qualifier="level">Doctor of Philosophy</dim:field>
   <dim:field mdschema="thesis" element="degree" qualifier="name">Ph. D., Biomedical Engineering</dim:field>
   <dim:field mdschema="dspace" element="entity" qualifier="type">Publication</dim:field>
   <dim:field mdschema="cris" element="virtual" qualifier="collection" authority="https://cornell-ecommons.eks.prod.4science.cloud/handle/1813/47" confidence="600">Cornell Theses and Dissertations</dim:field>
   <dim:field mdschema="cris" element="virtual" qualifier="author" lang="en_US">Rosenthal, Joseph</dim:field>
   <dim:field mdschema="cris" element="virtualsource" qualifier="collection">5893a6ea-7af3-41d7-abc6-04bcd26ab5df</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
   <dim:field mdschema="cerif" element="openaire" authority="" confidence="-1">&lt;Publication xmlns="https://www.openaire.eu/cerif-profile/1.1/" id="baf82a2b-6384-4d50-b6f3-785923afb533">
	&lt;Type xmlns="https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types">http://purl.org/coar/resource_type/c_1843&lt;/Type>
	&lt;Language>en_US&lt;/Language>
   	&lt;Title>Engineered Outer Membrane Vesicles Derived From Probiotic Escherichia Coli Nissle 1917 As Recobinant Subunit Antigen Carreirs For The Development Of Pathogen-Mimetic Vaccines&lt;/Title>
   	&lt;PublishedIn>
    	&lt;Publication>
      	&lt;/Publication>
   	&lt;/PublishedIn>
   	&lt;PublicationDate>2014-05-25&lt;/PublicationDate>
   	&lt;Authors>
      	&lt;Author>
        	&lt;DisplayName>Rosenthal, Joseph&lt;/DisplayName>
         	&lt;Affiliation>
         		&lt;OrgUnit>
         		&lt;/OrgUnit>
         	&lt;/Affiliation>
      	&lt;/Author>
	&lt;/Authors>
   	&lt;Editors>
	&lt;/Editors>
    &lt;Publishers>
        &lt;Publisher>
            &lt;OrgUnit />
        &lt;/Publisher>
    &lt;/Publishers>
    &lt;Keyword>Outer membrane vesicle&lt;/Keyword>
    &lt;Keyword>Vaccine delivery&lt;/Keyword>
    &lt;Keyword>Pathogen-like particle&lt;/Keyword>
   	&lt;Abstract>The greatest strides in vaccine delivery over the last decade have come primarily from a new class of nanoparticulate antigen carrier that focuses on reverse-engineering the pathogen-immune cell interaction on the molecular level. Such &amp;quot;pathogen-like particles&amp;quot;, or PLPs, take an elegant approach to biomimicry, attempting to artificially isolate or recreate a pathogen&amp;apos;s natural ability to stimulate a targeted immune response. In this work, we focused on the transformation of the probiotic E. coli strain Nissle 1917 into an outer membrane vesicle (OMV) platform for TH1-biasing delivery of a variety of recombinant antigens. We hypothesize that by harnessing the natural immunomodulation of the Nissle 1917 (EcN) bacterium, and pairing this immunomodulation with appropriate vaccine targets that require potent TH1-biasing vaccine responses, we can engineer a recombinant antigen delivery platform that uniquely enhances antigen-specific immunity through pathogen-mimetic vaccination. As bionanoparticulate PLPs often suffer from requiring multiple boosts and external adjuvants to achieve pathogen-mimetic memory responses, we further enhanced our EcN OMV platform with controlled release delivery using injectable polymeric microspheres as a transient OMV depot. From the immunological characterization of free and encapsulated EcN OMVs&amp;apos; vaccine capability, two vaccine targets were chosen to demonstrate the efficacy of the OMVs as a PLP platform for vaccine delivery. To test the capacity of the OMVs to functionally display and vaccinate against a heterologous antigen of viral origin, OMVs expressing a subunit of H1N1 hemagglutinin were produced and tested on BALB/c mice. Not only did the resulting immunological assays for vaccine response show great promise for a protective response, generating a 2.6-fold increase in IgG2a:IgG1 titers and a 8.1iii  fold increase in IFN-[gamma]:IL-4 T-cell secretion versus a gold-standard control, but further analysis using hemagglutination-inhibition assays demonstrated &amp;gt;50-fold enhancement in cross-strain protection against H3N2. Secondly, to test EcN OMVs&amp;apos; capacity to direct unique immunomodulation to less standard vaccine targets, OMVs expressing the peanut allergen Arah2 were produced as both a prophylactic vaccine (for preventing peanut allergy) and an immunotherapy (for treating extent peanut allergy). Using a BALB/c mouse model for peanut allergy sensitization, a free EcN OMV vaccine dose was administered prior to sensitization, which following anaphylactic challenge post-sensitization resulted in protective survival of 100% of vaccinated mice. Encapsulated controlled release of lower doses of the Arah2-displaying EcN OMVs administered following sensitization were also successful at protecting &amp;gt;50% of mice from some level of anaphylaxis post-challenge while minimizing side-effects relative to traditional sublingual immunotherapy. The engineering and in vitro/in vivo testing of EcN OMVs as vaccine antigen carriers demonstrated promising efficacy as a pathogen-mimetic platform for protective immunomodulation. Successful testing with a variety of recombinant antigens provides the foundation upon which further development of the EcN OMV platform can lead to a promising host of PLP vaccines. iv&lt;/Abstract>
	&lt;Access xmlns="http://purl.org/coar/access_right" 
    >
    &lt;/Access>
&lt;/Publication>
</dim:field>
</dim:dim>
</metadata></record></GetRecord></OAI-PMH>